AI Pharma & Biotech Fundraising Guide (2026)

How AI drug discovery, generative biology, and TechBio startups raise capital in 2026 against Isomorphic Labs, Recursion, Insilico, Xaira, and pharma M&A.

Raising Capital for AI Pharma & Biotech Startups

AI pharma, generative biology is the 2025-2026 TechBio thesis after multiple AI-designed molecules entered clinical trials, Nobel Chemistry 2024 (Baker, Hassabis, Jumper): Isomorphic Labs (Alphabet spinout 2021, ~$600M raised Apr 2025 — Thrive+GV+Isomorphic parent — first external round Apr 2025 valuing at $2.5-3B rumored — AlphaFold3, Novartis, Lilly deals), Xaira Therapeutics (~$1B seed Apr 2024 — ARCH+Foresite+F-Prime+NEA+Sequoia+Lux+Menlo+Two Sigma+Lightspeed+Section 32+Uphonest — David Baker, Marc Tessier-Lavigne — largest biotech seed ever), Recursion Pharma ($RXRX public ~$1.5B mcap 2025 — Salesforce/Nvidia-partnered, merged Exscientia Aug 2024), Insilico Medicine (~$400M raised — INS018_055 Phase II idiopathic pulmonary fibrosis), Genesis Therapeutics (~$275M raised, Andreessen+NEA+Rock Springs — $1B — small molecule AI), Terray Therapeutics (~$150M raised — Sanofi+Merck+Bristol partnerships), Iambic Therapeutics (~$150M raised — Pfizer+Nvidia partnership), Latent Labs (~$50M — Radical+Kindred+Grok), EvolutionaryScale (~$142M — Nat Friedman+Daniel Gross+Amazon+Nvidia — ESM3 protein language model), Cradle Bio (~$73M — Index+Kindred+Two Sigma — enzyme design), Chai Discovery (~$30M — OpenAI Startup Fund+Thrive+Dimension — Chai-1 open-source AlphaFold competitor), Profluent Bio (~$45M — Air Street+Convergent+Insight — protein LM), Basecamp Research (~$60M — Redalpine+Hummingbird — genomic data), Retro Biosciences (~$180M — Sam Altman personal — longevity), Altos Labs ($3B seed 2022 — Bezos+Yuri Milner — cellular reprogramming), Formation Bio (~$372M raised, Andreessen+Sanofi+Sequoia — $1B — AI clinical trials, platform pharma), Absci ($ABSI public ~$400M — antibody de novo), Generate Biomedicines ($TGB — reset, $700M+ raised — Flagship), Valence Labs (Recursion acquired — GNN, academia), BenchSci ($95M raised — literature AI), Owkin ($300M+ raised — federated pharma AI), Nabla Bio (~$30M raised — Radical — antibody design), Cellarity ($200M+ raised — Flagship — network biology), Deep Genomics ($55M — pivoted), BenevolentAI ($BAI — LSE public reset). Pharma primes AI-native, M&A: Novartis ($NVS, Isomorphic $1.2B deal Jan 2024), Eli Lilly ($LLY, Isomorphic $1.7B deal Jan 2024, OpenAI partnership 2024), Pfizer ($PFE, Iambic, XtalPi), Bristol-Myers Squibb ($BMY, Exscientia precedent), AstraZeneca ($AZN, BenevolentAI reset, Absci deal 2024), Sanofi ($SNY, Formation Bio $1B strategic 2024, Insilico partnership), Amgen ($AMGN, Generate Biomedicines), Merck ($MRK, Terray), Roche ($RHHBY, Recursion, Exscientia). Nobel 2024 chemistry: David Baker (Rosetta, RFdiffusion), Demis Hassabis, John Jumper (AlphaFold) validated AI-designed proteins. Clinical, regulatory gates: FDA IND, Phase I/II/III, EMA, PMDA, NMPA (China), GxP (GLP/GMP/GCP), 21 CFR Part 11, IRB, ICH E6(R3) GCP, PDUFA VIII 2027, FDA AI/ML Software as Medical Device (SaMD) draft guidance 2024, EU AI Act medical device high-risk. Winners target: (1) AI-native drug discovery platform, pharma pipeline (Isomorphic $2.5B rumored, Xaira $1B seed, Insilico, Genesis, Terray, Iambic — platform, programs, biggest pharma partnerships), (2) protein language model / foundation model for biology (EvolutionaryScale ESM3, Chai-1 open-source, Profluent, Cradle enzyme, Latent Labs), (3) AI clinical trials, operations (Formation Bio $1B, Unlearn AI, Deep 6 AI, Owkin federated), (4) longevity, cell reprogramming (Altos Labs $3B seed, Retro Biosciences), (5) antibody, protein de novo (Absci public, Nabla Bio, Xaira antibody arm).

Why 2026 is different (Nobel 2024, Isomorphic external round, Xaira $1B seed, Sanofi Formation Bio $1B)

Nobel Chemistry 2024 (David Baker Rosetta, RFdiffusion, Demis Hassabis, John Jumper AlphaFold) validated AI-designed proteins as clinically real. Isomorphic Labs $600M first external round Apr 2025 (Alphabet, Thrive, GV rumored $2.5-3B valuation), $1.2B Novartis, $1.7B Eli Lilly deals Jan 2024. Xaira Therapeutics $1B seed Apr 2024 (largest biotech seed ever, David Baker, Marc Tessier-Lavigne co-founders, ARCH+Foresite+F-Prime+NEA+Sequoia+Lux+Menlo+Two Sigma+Lightspeed+Section 32). Insilico Medicine INS018_055 Phase IIa idiopathic pulmonary fibrosis 2024 (first fully AI-designed drug in Phase II). Recursion, Exscientia merger Aug 2024 ($690M all-stock $RXRX). Genesis Therapeutics $1B valuation, $200M Series B May 2024. Formation Bio $1B, Sanofi $1B strategic Jul 2024 (largest AI-clinical-trials deal). EvolutionaryScale ESM3 $142M (Nat Friedman, Daniel Gross, Amazon, Nvidia). Chai Discovery Chai-1 open-source AlphaFold3 competitor. AlphaFold3 (Isomorphic, DeepMind May 2024 released restricted-use), Boltz-1 MIT open, RoseTTAFold, RFdiffusion open, Meta ESM3 open, Nvidia BioNeMo = foundation model layer democratized. Pharma-in-house AI arms race: Novartis, Lilly, Pfizer, BMS, AZ, GSK, Roche, Sanofi, Amgen, Merck, Bayer all announced AI drug discovery centers 2023-2025. Winners 2026: AI drug discovery platform with wholly-owned pipeline, pharma partnership, benchmark leadership, wet-lab-in-the-loop, modality specialization, data moat.

Realistic capital stack

Seed: $10M-$1B (biotech seeds much larger than SaaS — Xaira $1B seed 2024 largest ever, Altos $3B seed 2022 Bezos+Yuri Milner, Retro Biosciences $180M Sam Altman-led). Series A: $50-300M. Series B: $100M-$500M. Growth: $300M-$3B (biotech crossovers). Reference: Isomorphic Labs (Alphabet spinout 2021, $600M external round Apr 2025 rumored $2.5-3B — Thrive+GV+Foresite+NEA+Sequoia+Section 32 rumored syndicate, Novartis $1.2B Jan 2024, Lilly $1.7B Jan 2024 partnerships), Xaira Therapeutics ($1B seed Apr 2024 largest ever — ARCH+Foresite+F-Prime+NEA+Sequoia+Lux+Menlo+Two Sigma+Lightspeed+Section 32+Uphonest+SV Angel+Y Combinator), Recursion $RXRX (~$1.5B mcap 2025, ~$450M raised private, Sept 2021 IPO $2.9B, Exscientia merger $690M Aug 2024, Roche $150M, Bayer $109M, Merck KGaA, Nvidia partnership), Insilico Medicine ($400M+ raised — Warburg+Baillie Gifford+CPP+Sequoia China+B Capital+Qiming), Genesis Therapeutics ($275M raised — Andreessen+NEA+Rock Springs+T. Rowe+Founders Fund — $1B May 2024), Terray Therapeutics ($150M raised — Sanofi+Merck+Bristol partnerships), Iambic Therapeutics ($150M raised — Pfizer+Nvidia+Ascenta+Nextech), Latent Labs ($50M — Radical+Kindred+Grok), EvolutionaryScale ($142M seed 2024 — Nat Friedman+Daniel Gross+Amazon+Nvidia+Lux), Cradle Bio ($73M — Index+Kindred+Two Sigma), Chai Discovery ($30M — OpenAI Startup Fund+Thrive+Dimension), Profluent Bio ($45M — Air Street+Convergent+Insight), Basecamp Research ($60M — Redalpine+Hummingbird), Retro Biosciences ($180M raised — Sam Altman personal), Altos Labs ($3B seed 2022 — Bezos+Yuri Milner+ARCH+GV+F-Prime), Formation Bio ($372M raised — Andreessen+Sanofi+Sequoia+Emerson+Adage+Human Longevity, $1B Sanofi strategic Jul 2024), Absci $ABSI (~$400M mcap, ~$230M raised private, IPO Jul 2021 $1.6B, AstraZeneca 2024 deal, Merck 2024 deal), Generate Biomedicines ($700M+ raised — Flagship+Amgen+Nvidia+ARCH+Bayer Leaps), Owkin ($300M+ raised — Softbank+MState+F-Prime+Fidelity+GV+Cathay), BenchSci ($95M raised — Inovia+F-Prime+Nvidia), BenevolentAI $BAI (LSE public reset, ~$300M raised private, 2022 SPAC reset), Cellarity ($200M+ raised — Flagship+Kleiner+FootPrint+Softbank). Exits, M&A: Recursion, Exscientia merger Aug 2024 $690M all-stock, Deep Genomics pivoted, Saama Technologies → Merck $150M 2022, Nimbus Therapeutics TYK2 → Takeda $6B Jan 2023 (largest AI-adjacent biotech deal), MyoKardia → BMS $13B 2020, Prometheus → Merck $10.8B 2023, Karuna → BMS $14B 2024, ImmunoGen → AbbVie $10.1B 2023, Cerevel → AbbVie $8.7B 2023, Alpine Immune → Vertex $4.9B 2024, Karolinska Kymera partnerships, Vertex Alpine $4.9B 2024. Pharma-M&A biotech ceiling $6-14B typical, $30B+ rare (Seagen → Pfizer $43B 2023 largest recent). Isomorphic, Xaira, Insilico, Genesis IPO probable 2026-2028 if lead assets progress.

Frequently asked questions

AI drug discovery platform vs foundation model vs clinical trials vs longevity vs de novo antibody?
AI drug discovery platform, pharma pipeline (Isomorphic $2.5-3B rumored, Xaira $1B seed 2024 largest ever, Insilico Phase II, Genesis $1B, Recursion, Exscientia $1.5B public, Terray, Iambic Pfizer+Nvidia, Absci $ABSI, Generate Flagship, Cellarity, Owkin) — highest valuations because platform, wholly-owned pipeline unlocks pharma-partnership revenue AND asset value. Foundation model for biology (EvolutionaryScale ESM3, Chai-1 open-source, Profluent, Cradle, Latent Labs, Basecamp) — Baker Nobel 2024 validation. AI clinical trials (Formation Bio $1B Sanofi, Unlearn AI digital twin, Deep 6, Owkin federated) — 30-50% trial-timeline reduction. Longevity, cell reprogramming (Altos $3B seed 2022 Bezos+Yuri Milner, Retro $180M Sam Altman, NewLimit, BioAge public reset, Rejuvenate). De novo antibody, protein (Absci public, Nabla, Xaira antibody arm, Genesis). 2026 best wedges: platform, pipeline (Isomorphic, Xaira pattern), foundation model (post-Nobel, open-source), AI clinical trials (Sanofi, Formation Bio pattern).
How to beat Isomorphic, Xaira, pharma in-house AI, open-source AlphaFold3?
Isomorphic (Alphabet, AlphaFold3, Novartis $1.2B, Lilly $1.7B, $600M external Apr 2025 $2.5-3B rumored), Xaira ($1B seed 2024 largest ever, Baker Nobel, Marc Tessier-Lavigne), Insilico (Phase II), Recursion, Exscientia ($1.5B public), pharma-in-house AI (Novartis, Lilly OpenAI partnership 2024, Isomorphic LP, BMS, Absci, AZ, BenevolentAI, Absci, GSK Genomics England, Roche gRED, Sanofi, Formation $1B, Insilico, Amgen, Generate, Pfizer, Iambic, XtalPi, Bayer Leaps, Recursion), open-source foundation models (AlphaFold3 restricted-use, Chai-1 open, ESM3 open, Boltz-1 MIT open, RFdiffusion, RoseTTAFold Baker Lab open, Nvidia BioNeMo, Meta ESM3 open) = incumbent, open, pharma-in-house competition. Survive with: (1) wholly-owned pipeline platforms convert to (platform, programs — pharma pays for de-risked assets), (2) benchmark leadership (CASP, CAMEO, ProteinGym, Boltz, BindCraft), (3) data moat pharma, open-source can't replicate (Basecamp genomic, Recursion phenomap, Insitro imaging, Owkin federated multi-hospital, Retro cell-reprogramming), (4) wet-lab, AI cycle speed (integrated in-house lab-in-the-loop vs pharma-outsourced iteration weeks/months → hours/days), (5) modality specialization (small molecule vs antibody vs enzyme vs cell reprogramming vs multi-modal), (6) pharma partnership economics (upfront, milestones, royalty — Isomorphic $37.5M Novartis upfront, Sanofi $180M Formation Bio upfront, $1B strategic — investors underwrite partnership NPV).
Exit paths?
Pharma M&A: Novartis ($NVS, Isomorphic $1.2B partnership Jan 2024), Eli Lilly ($LLY, Isomorphic $1.7B, OpenAI partnership 2024), Pfizer ($PFE, Iambic, XtalPi, Seagen $43B 2023 largest recent), Bristol-Myers Squibb ($BMY, Exscientia, MyoKardia $13B 2020, Karuna $14B 2024), AstraZeneca ($AZN, Absci 2024, BenevolentAI cautionary, Alexion $39B 2020), Sanofi ($SNY, Formation Bio $1B Jul 2024, Insilico), Amgen ($AMGN, Generate, Horizon $28B 2023), Merck ($MRK, Prometheus $10.8B 2023, Saama $150M 2022), Roche ($RHHBY, Recursion, Exscientia, gRED AI, Karolinska Kymera), GSK ($GSK, Autolus, Vir, Genomics England AI), Johnson & Johnson (Cerevel $8.7B 2023, Ambrx $2B 2024, Shockwave $13.1B 2024), AbbVie ($ABBV, ImmunoGen $10.1B 2023, Cerevel $8.7B 2023), Regeneron ($REGN), Vertex ($VRTX, Alpine Immune $4.9B 2024), Biogen, Takeda (Nimbus TYK2 $6B Jan 2023 largest AI-adjacent, Shire $62B precedent), Novo Nordisk, Boehringer Ingelheim, Bayer (Recursion partnership, Leaps $1.5B fund). Public IPO: probable for scaled platforms with wholly-owned pipeline (Isomorphic, Xaira, Insilico, Genesis rumored 2026-2028 — Recursion $RXRX Sept 2021 IPO $2.9B, Absci $ABSI Jul 2021 IPO $1.6B, Formation Bio, Cellarity, Generate, Iambic Roche-Merck-BMS-partnered pipeline). Pharma-M&A biotech ceiling $6-14B typical, $28-43B rare (Seagen → Pfizer $43B 2023, Horizon → Amgen $28B 2023, Alexion → AZ $39B 2020, Shire → Takeda $62B 2019). Deal size $500M-$14B typical for lead-asset-de-risked; $30-60B rare pharma-of-pharma. AI-drug-designed clinical readouts 2026-2028 will define next M&A cycle.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database